Dysregulation of sterol regulatory element-binding protein 2 gene in HIV treatment-experienced individuals

Autoři: Anuoluwapo Sopeyin aff001;  Lei Zhou aff001;  Min Li aff001;  Lydia Barakat aff002;  Elijah Paintsil aff001
Působiště autorů: Department of Pediatrics, Yale University School of Medicine, New Haven, Connecticut, United States of America aff001;  Department of Medicine, Yale University School of Medicine, New Haven, Connecticut, United States of America aff002;  Department of Pharmacology, Yale University School of Medicine, New Haven, Connecticut, United States of America aff003;  School of Public Health, Yale University, New Haven, Connecticut, United States of America aff004
Vyšlo v časopise: PLoS ONE 14(12)
Kategorie: Research Article
doi: 10.1371/journal.pone.0226573


Although antiretroviral therapy (ART) has resulted in a marked decrease in AIDS-related morbidity and mortality, the therapeutic benefit is often limited by side effects such as metabolic derangement such as lipodystrophy and hyperlipidemia and cardiovascular diseases. These side effects are pervasive in people living with HIV (PLWH). However, the underlying mechanisms are not completely understood. We investigated the effects of ART on cholesterol biosynthesis genes. This is a retrospective analysis of data and specimens collected during a cross-sectional, case-control study of ART-induced toxicity. Cases were HIV treatment-experienced individuals with HIV viral suppression and no diagnosis of ART-associated toxicity (n = 18), and controls were HIV-uninfected individuals (n = 18). The mRNA expressions of 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) and ATP binding cassette transporter A1 (ABCA1) were significantly upregulated in cases (HIV+) compared to controls (HIV-), as well as the corresponding protein expression level of HMGCR. We observed dysregulation between sterol regulatory element-binding protein 2 (SREBP-2, sensory control) and HMGCR and low-density lipoprotein receptor (LDLR) pathways. Dysregulation of cholesterol biosynthesis genes may predate clinical manifestation of ART-induced lipid abnormalities.

Klíčová slova:

Biosynthesis – Gene expression – Cholesterol – Protein expression – Viral gene expression – Sterols


1. Brinkman K, ter Hofstede HJ, Burger DM, Smeitink JA, Koopmans PP. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway. Aids. 1998;12(14):1735–44. doi: 10.1097/00002030-199814000-00004 9792373

2. Lopez S, Miro O, Martinez E, Pedrol E, Rodriguez-Santiago B, Milinkovic A, et al. Mitochondrial effects of antiretroviral therapies in asymptomatic patients. Antivir Ther. 2004;9(1):47–55. 15040536

3. Montaner JS, Cote HC, Harris M, Hogg RS, Yip B, Harrigan PR, et al. Nucleoside-related mitochondrial toxicity among HIV-infected patients receiving antiretroviral therapy: insights from the evaluation of venous lactic acid and peripheral blood mitochondrial DNA. Clin Infect Dis. 2004;38 Suppl 2:S73–9.

4. Moyle G. Clinical manifestations and management of antiretroviral nucleoside analog-related mitochondrial toxicity. Clin Ther. 2000;22(8):911–36; discussion 898. doi: 10.1016/S0149-2918(00)80064-8 10972629

5. Gardner K, Hall PA, Chinnery PF, Payne BA. HIV Treatment and Associated Mitochondrial Pathology: Review of 25 Years of in Vitro, Animal, and Human Studies. Toxicol Pathol. 2013.

6. Grundy SM. Metabolic syndrome scientific statement by the American Heart Association and the National Heart, Lung, and Blood Institute. Arteriosclerosis, thrombosis, and vascular biology. 2005;25(11):2243–4. doi: 10.1161/01.ATV.0000189155.75833.c7 16258150

7. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet. 1999;353(9170):2093–9. doi: 10.1016/S0140-6736(98)08468-2 10382692

8. Aguilar M, Bhuket T, Torres S, Liu B, Wong RJ. Prevalence of the Metabolic Syndrome in the United States, 2003-2012. JAMA. 2015;313(19):1973–4. doi: 10.1001/jama.2015.4260 25988468

9. Henry K, Melroe H, Huebsch J, Hermundson J, Levine C, Swensen L, et al. Severe premature coronary artery disease with protease inhibitors. Lancet. 1998;351(9112):1328.

10. Zanni MV, Schouten J, Grinspoon SK, Reiss P. Risk of coronary heart disease in patients with HIV infection. Nat Rev Cardiol. 2014;11(12):728–41. doi: 10.1038/nrcardio.2014.167 25331088

11. Willig AL, Overton ET. Metabolic Complications and Glucose Metabolism in HIV Infection: A Review of the Evidence. Curr HIV/AIDS Rep. 2016;13(5):289–96. doi: 10.1007/s11904-016-0330-z 27541600

12. Nguyen KA, Peer N, Mills EJ, Kengne AP. A Meta-Analysis of the Metabolic Syndrome Prevalence in the Global HIV-Infected Population. PLoS One. 2016;11(3):e0150970. doi: 10.1371/journal.pone.0150970 27008536

13. den Brinker M, Wit FW, Wertheim-van Dillen PM, Jurriaans S, Weel J, van Leeuwen R, et al. Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection. AIDS. 2000;14(18):2895–902. doi: 10.1097/00002030-200012220-00011 11153671

14. Savès M, Raffi F, Clevenbergh P, Marchou B, Waldner-Combernoux A, Morlat P, et al. Hepatitis B or hepatitis C virus infection is a risk factor for severe hepatic cytolysis after initiation of a protease inhibitor-containing antiretroviral regimen in human immunodeficiency virus-infected patients. The APROCO Study Group. Antimicrob Agents Chemother. 2000;44(12):3451–5. doi: 10.1128/aac.44.12.3451-3455.2000 11083658

15. Saag M, Balu R, Phillips E, Brachman P, Martorell C, Burman W, et al. High sensitivity of human leukocyte antigen-b*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients. Clin Infect Dis. 2008;46(7):1111–8. doi: 10.1086/529382 18444831

16. Li M, Sopeyin A, Paintsil E. Combination of Tenofovir and Emtricitabine with Efavirenz Does Not Moderate Inhibitory Effect of Efavirenz on Mitochondrial Function and Cholesterol Biosynthesis in Human T Lymphoblastoid Cell Line. Antimicrob Agents Chemother. 2018;62(9).

17. Selvaraj S, Ghebremichael M, Li M, Foli Y, Langs-Barlow A, Ogbuagu A, et al. Antiretroviral therapy-induced mitochondrial toxicity: potential mechanisms beyond polymerase-gamma inhibition. Clin Pharmacol Ther. 2014;96(1):110–20. doi: 10.1038/clpt.2014.64 24637942

18. Tuttle DL, Anders CB, Aquino-De Jesus MJ, Poole PP, Lamers SL, Briggs DR, et al. Increased replication of non-syncytium-inducing HIV type 1 isolates in monocyte-derived macrophages is linked to advanced disease in infected children. AIDS Res Hum Retroviruses. 2002;18(5):353–62. doi: 10.1089/088922202753519133 11897037

19. Lu L, Katsaros D, Wiley A, Rigault de la Longrais IA, Puopolo M, Yu H. Expression of MDR1 in epithelial ovarian cancer and its association with disease progression. Oncol Res. 2007;16(8):395–403. doi: 10.3727/000000006783980892 17913048

20. Paintsil E, Dutschman GE, Hu R, Grill SP, Wang C-J, Lam W, et al. Determinants of individual variation in intracellular accumulation of anti-HIV nucleoside analog metabolites. Antimicrobial agents and chemotherapy. 2011;55(2):895–903. doi: 10.1128/AAC.01303-10 21078952

21. Lewington S, Whitlock G, Clarke R, Sherliker P, Emberson J, Halsey J, et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet. 2007;370(9602):1829–39. doi: 10.1016/S0140-6736(07)61778-4 18061058

22. Attie AD, Seidah NG. Dual regulation of the LDL receptor—some clarity and new questions. Cell metabolism. 2005;1(5):290–2. doi: 10.1016/j.cmet.2005.04.006 16054075

23. Friesen JA, Rodwell VW. The 3-hydroxy-3-methylglutaryl coenzyme-A (HMG-CoA) reductases. Genome biology. 2004;5(11):248. doi: 10.1186/gb-2004-5-11-248 15535874

24. Carr A. Toxicity of antiretroviral therapy and implications for drug development. Nat Rev Drug Discov. 2003;2(8):624–34. doi: 10.1038/nrd1151 12904812

25. Brown MS, Goldstein JL. The SREBP Pathway: Regulation of Cholesterol Metabolism by Proteolysis of a Membrane-Bound Transcription Factor. Cell. 1997;89(3):331–40. doi: 10.1016/s0092-8674(00)80213-5 9150132

26. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature. 1990;343(6257):425–30. doi: 10.1038/343425a0 1967820

27. Horie T, Ono K, Horiguchi M, Nishi H, Nakamura T, Nagao K, et al. MicroRNA-33 encoded by an intron of sterol regulatory element-binding protein 2 (Srebp2) regulates HDL in vivo. Proceedings of the National Academy of Sciences of the United States of America. 2010;107(40):17321–6. doi: 10.1073/pnas.1008499107 20855588

28. Feeney ER, McAuley N, O’Halloran JA, Rock C, Low J, Satchell CS, et al. The expression of cholesterol metabolism genes in monocytes from HIV-infected subjects suggests intracellular cholesterol accumulation. J Infect Dis. 2013;207(4):628–37. doi: 10.1093/infdis/jis723 23204179

29. Maisa A, Hearps AC, Angelovich TA, Pereira CF, Zhou J, Shi MD, et al. Monocytes from HIV-infected individuals show impaired cholesterol efflux and increased foam cell formation after transendothelial migration. AIDS. 2015;29(12):1445–57. doi: 10.1097/QAD.0000000000000739 26244384

30. Bodzioch M, Orsó E, Klucken J, Langmann T, Böttcher A, Diederich W, et al. The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease. Nat Genet. 1999;22(4):347–51. doi: 10.1038/11914 10431237

31. Brooks-Wilson A, Marcil M, Clee SM, Zhang LH, Roomp K, van Dam M, et al. Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency. Nat Genet. 1999;22(4):336–45. doi: 10.1038/11905 10431236

32. Thangavel S, Mulet CT, Atluri VSR, Agudelo M, Rosenberg R, Devieux JG, et al. Oxidative Stress in HIV Infection and Alcohol Use: Role of Redox Signals in Modulation of Lipid Rafts and ATP-Binding Cassette Transporters. Antioxidants & redox signaling. 2018;28(4):324–37.

33. Mujawar Z, Rose H, Morrow MP, Pushkarsky T, Dubrovsky L, Mukhamedova N, et al. Human immunodeficiency virus impairs reverse cholesterol transport from macrophages. PLoS biology. 2006;4(11):e365. doi: 10.1371/journal.pbio.0040365 17076584

34. Asztalos BF, Mujawar Z, Morrow MP, Grant A, Pushkarsky T, Wanke C, et al. Circulating Nef induces dyslipidemia in simian immunodeficiency virus-infected macaques by suppressing cholesterol efflux. J Infect Dis. 2010;202(4):614–23. doi: 10.1086/654817 20617930

35. Cui HL, Ditiatkovski M, Kesani R, Bobryshev YV, Liu Y, Geyer M, et al. HIV protein Nef causes dyslipidemia and formation of foam cells in mouse models of atherosclerosis. FASEB journal: official publication of the Federation of American Societies for Experimental Biology. 2014;28(7):2828–39.

36. Lo J, Rosenberg ES, Fitzgerald ML, Bazner SB, Ihenachor EJ, Hawxhurst V, et al. High-density lipoprotein-mediated cholesterol efflux capacity is improved by treatment with antiretroviral therapy in acute human immunodeficiency virus infection. Open Forum Infect Dis. 2014;1(3):ofu108.

37. Dawson PA, Hofmann SL, van der Westhuyzen DR, Sudhof TC, Brown MS, Goldstein JL. Sterol-dependent repression of low density lipoprotein receptor promoter mediated by 16-base pair sequence adjacent to binding site for transcription factor Sp1. The Journal of biological chemistry. 1988;263(7):3372–9. 3277969

38. Smith JR, Osborne TF, Brown MS, Goldstein JL, Gil G. Multiple sterol regulatory elements in promoter for hamster 3-hydroxy-3-methylglutaryl-coenzyme A synthase. The Journal of biological chemistry. 1988;263(34):18480–7. 2903862

Článek vyšel v časopise


2019 Číslo 12